Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

Dragn Trailer. Peter Webber's Dragn (2025) movie trailer has been released by Cineverse. The Dragn trailer stars James Paxton ...

Background The epidemiology and long-term healthcare utilisation associated with chronic kidney disease (CKD) among those ...

Eli Lilly ( LLY 1.01%) is the most valuable healthcare company in the world, as its valuation hovers around $1 trillion. It ...

Lilly has performed well in recent years thanks to major breakthroughs, especially in diabetes and weight management. And ...

BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...

Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of ...

Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.

Retatrutide helped trial participants lose up to 28.7% of their body weight, but experts warn about excessive weight loss.

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.

An experimental therapy for a rare blood cancer was rejected by the FDA though internal reviewers had recommended it be cleared ...